Recent Updates — INV

Innventure's Board formed a Strategic Review Committee of disinterested directors, working with independent financial advisors, to oversee a range of strategic matters including an evaluation of capital strategies. The company highlighted significant cost reduction initiatives, noting a headcount decrease from 40 to 15 employees since the end of Q1 2026, which reduced payroll costs by approximately 57%. Innventure established an at-the-market equity offering program on October 6, 2026, to address near-term liquidity needs while aiming to minimize dilution. The company intends to conclude funding for AeroFlexx within the next month and Refinity by year-end, while supporting independent fundraising efforts at its operating companies. Innventure builds and scales companies that commercialize new technologies.

Innventure, Inc. received a notice from Nasdaq stating its common stock failed to maintain the required minimum closing bid price of $1.00 for thirty consecutive business days ending October 22, 2026. The company has an initial compliance period until April 21, 2027, to regain compliance by maintaining a bid price above $1.00 for at least ten consecutive business days. Failure to comply may result in delisting from the Nasdaq Global Market or a transfer to the Nasdaq Capital Market if additional listing standards are met. Innventure operates as a biotechnology company focused on developing therapies for rare diseases.

Innventure appointed Eric Stober as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer. Outgoing CFO David Yablunosky ceased employment on October 19, 2026, and entered a consulting agreement to provide transition services through May 14, 2027 for $5,500 per week. Additionally, Chief Growth Officer Roland Austrup will end his service on October 31, 2026, as the company consolidates finance, accounting, investor relations and communications under Stober. Innventure develops and commercializes medical devices.

Innventure entered into an at-the-market (ATM) equity offering agreement providing access to up to $60 million in capital, while simultaneously discontinuing its standby equity purchase agreement with YA II PN, Ltd. The ATM allows the company flexibility to sell common stock over time based on market conditions and board-approved parameters. This move replaces the previous SEPA arrangement established in October 2023, aiming to broaden financing options and give management greater control over capital raising timing and dilution. Innventure builds, scales, and operates companies that commercialize new technologies.

Innventure, Inc. entered into an At The Market Offering Agreement with Lucid Capital Markets, LLC on October 6, 2026, establishing a facility to sell up to $60 million of its common stock at the company's discretion. Lucid will act as sales agent or principal, charging commissions ranging from 2.17% to 3.0%. The company intends to use net proceeds for working capital and general corporate purposes, including executing a strategic transformation focused on Accelsius Holdings LLC and potentially acquiring additional units of that subsidiary. Concurrently, Innventure announced it does not intend to issue further shares under its existing Standby Equity Purchase Agreement with Yorkville. Innventure operates in the technology sector, focusing on digital health solutions and strategic investments.